Daniel Junius - IDEXX Laboratories Independent Director
| IDXX Stock | USD 491.29 6.50 1.31% |
Director
Mr. Daniel M. Junius is Independent Director of IDEXX Laboratories, Inc. Mr. Junius was President and Chief Executive Officer of ImmunoGen, Inc. from 2009 until his retirement in May 2016. Before that, he served as President and Chief Operating Officer and Acting Chief Financial Officer of ImmunoGen from July 2008 to December 2008, Executive Vice President and Chief Financial Officer from 2006 to July 2008, and Senior Vice President and Chief Financial Officer from 2005 to 2006. Before joining ImmunoGen, Mr. Junius was Executive Vice President and Chief Financial Officer of New England Business Service, Inc. from 2002 until its acquisition by Deluxe Corporation in 2004, and he was Senior Vice President and Chief Financial Officer of New England Business Services from 1998 to 2002. Before joining New England Business Services, Mr. Junius was Vice President and Chief Financial Officer of Nashua Corporation from 1996 to 1998. Mr. Junius joined Nashua Corporation in 1984 and held various financial management positions of increasing responsibility before becoming Chief Financial Officer of Nashua Corporation in 1996. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a Masters in Management from Northwestern Universitys Kellogg School of Management. As the former Chief Executive Officer and Chief Financial Officer of ImmunoGen, a public biotechnology company, Mr. Junius has extensive leadership, management, strategic planning and financial experience in the biotechnology field. Over the course of almost 20 years as the chief financial officer of various companies, Mr. Junius gained substantial expertise in the review and preparation of financial statements, which provides valuable perspective as the Chair of the Audit Committee. Mr. Juniuss service on other public company boards, including as audit committee chair, brings additional insight to his Board service and leadership. since 2014.
| Age | 65 |
| Tenure | 10 years |
| Address | One IDEXX Drive, Westbrook, ME, United States, 04092 |
| Phone | 207 556 0300 |
| Web | https://www.idexx.com |
IDEXX Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.2283 % which means that it generated a profit of $0.2283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.8074 %, meaning that it created $0.8074 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IDEXX Laboratories' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.27 in 2024, whereas Return On Capital Employed is likely to drop 0.26 in 2024. At this time, IDEXX Laboratories' Return On Assets are fairly stable compared to the past year.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Leopold Swergold | Select Medical Holdings | 77 | |
| Charles Elson | Encompass Health Corp | 60 | |
| Lee Daniels | The Ensign Group | 61 | |
| Yvonne Curl | Encompass Health Corp | 65 | |
| Harold Paz | Select Medical Holdings | 62 | |
| Paul Abernathy | National HealthCare | 82 | |
| James Ely | Select Medical Holdings | 63 | |
| Ann Blouin | The Ensign Group | 65 | |
| Nancy Schlichting | Encompass Health Corp | 66 | |
| George Gaines | CryoCell International | 61 | |
| John Maupin | Encompass Health Corp | 73 | |
| Parvinderjit Khanuja | Select Medical Holdings | 62 | |
| Katherine Davisson | Select Medical Holdings | 53 | |
| Edward Shaw | Encompass Health Corp | 73 | |
| John Chidsey | Encompass Health Corp | 58 | |
| Lawrence Tucker | National HealthCare | 75 | |
| Jonathan Wheeler | CryoCell International | 55 | |
| Malene Davis | The Ensign Group | 55 | |
| John Nackel | The Ensign Group | 66 | |
| William Frist | Select Medical Holdings | 69 | |
| Richard LaRoche | National HealthCare | 74 | |
Management Performance
| Return On Equity | 0.81 | ||||
| Return On Asset | 0.23 |
IDEXX Laboratories Leadership Team
Elected by the shareholders, the IDEXX Laboratories' board of directors comprises two types of representatives: IDEXX Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IDEXX. The board's role is to monitor IDEXX Laboratories' management team and ensure that shareholders' interests are well served. IDEXX Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IDEXX Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathy Turner, Corporate Vice President | ||
| Sophie Vandebroek, Director | ||
| Jonathan Ayers, Chairman, CEO and Pres | ||
| William End, Lead Independent Director | ||
| Jacqueline Studer, Corporate Vice President General Counsel, Secretary | ||
| Johnny Powers, Executive VP | ||
| Rebecca Henderson, Independent Director | ||
| Michael Lane, Corporate Vice President General Manager | ||
| Anne Szostak, Independent Director | ||
| George Fennell, Senior Officer | ||
| Sharon Underberg, Corporate Vice President General Counsel, and Corporate Secretary | ||
| Ken Grady, Senior Officer | ||
| Jay Mazelsky, Executive VP | ||
| Stuart Essig, Independent Director | ||
| M Szostak, Independent Director | ||
| Bruce Claflin, Independent Director | ||
| Sam Samad, Independent Director | ||
| Barry Johnson, Independent Director | ||
| Giovani Twigge, Chief Human Resource Officer, Corporate Vice President | ||
| Nimrata PE, Sector Strategy | ||
| Martin Smith, Executive CTO | ||
| Jeffery Chadbourne, Director Reporting | ||
| Daniel Junius, Independent Director | ||
| Lawrence Kingsley, Independent Director | ||
| Kerry Bennett, Senior Labs | ||
| Thomas Craig, Independent Director | ||
| Michael Johnson, Executive Officer | ||
| Jonathan Mazelsky, CEO President | ||
| James Polewaczyk, Executive Officer | ||
| John Hart, Senior Operations | ||
| Michael Williams, Executive VP | ||
| Pat Venters, Chief Marketing Officer, Vice President | ||
| Brian McKeon, CFO, Principal Accounting Officer, Executive VP and Treasurer |
IDEXX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IDEXX Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.81 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 41.43 B | ||||
| Shares Outstanding | 83.05 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 92.75 % | ||||
| Number Of Shares Shorted | 1.76 M | ||||
| Price To Earning | 61.31 X |
IDEXX Laboratories Investors Sentiment
The influence of IDEXX Laboratories' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in IDEXX. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to IDEXX Laboratories' public news can be used to forecast risks associated with an investment in IDEXX. The trend in average sentiment can be used to explain how an investor holding IDEXX can time the market purely based on public headlines and social activities around IDEXX Laboratories. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
IDEXX Laboratories' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for IDEXX Laboratories' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average IDEXX Laboratories' news discussions. The higher the estimated score, the more favorable is the investor's outlook on IDEXX Laboratories.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards IDEXX Laboratories in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, IDEXX Laboratories' short interest history, or implied volatility extrapolated from IDEXX Laboratories options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for IDEXX Stock analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is IDEXX Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IDEXX Laboratories. If investors know IDEXX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IDEXX Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.121 | Earnings Share 10.07 | Revenue Per Share 44.073 | Quarterly Revenue Growth 0.088 | Return On Assets 0.2283 |
The market value of IDEXX Laboratories is measured differently than its book value, which is the value of IDEXX that is recorded on the company's balance sheet. Investors also form their own opinion of IDEXX Laboratories' value that differs from its market value or its book value, called intrinsic value, which is IDEXX Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IDEXX Laboratories' market value can be influenced by many factors that don't directly affect IDEXX Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IDEXX Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if IDEXX Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IDEXX Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.